Other
Research and development funding liability (Note 5)
Moderna Research and development funding liability (Note 5) decreased by 100.0% to $0 in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
Metric ID:
other_research_and_development_liability_currentHistorical Data
6 periods
| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $58M | $0 | $0 | $0 | $43M | $0 |
| QoQ Change | — | -100.0% | — | — | — | -100.0% |
| YoY Change | — | — | — | — | -25.9% | — |
Range$0 – $58M
CAGR-100.0%
Avg YoY Growth-25.9%
Median YoY Growth-25.9%
Current Streak2+ quarters decline
Frequently Asked Questions
- What is Moderna's research and development funding liability (note 5)?
- Moderna (MRNA) reported research and development funding liability (note 5) of $0 in Q1 2026.